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Background:  Both beta blockers and ivabradine showed to improve hyperemic coronary flow velocity and coronary flow reserve (CFR) in patients 
with stable coronary artery disease (CAD). There are no data on comparison of their effects. The purpose of this study was to assess the effects of 
ivabradine and bisoprolol on CFR in patients with stable CAD.
methods:  56 patients (37 M, 19 F; mean age 68±9 years) with stable CAD were enrolled in the study. Patients on beta blockers or ivabradine 
therapy, had a previous 2-week washout period from these drugs. Then baseline data were collected and all patients underwent Doppler-derived 
CFR. Coronary flow was assessed in the left anterior descending coronary artery (LAD), and was identified as the color signal directed from the base 
to the apex of the left ventricle, containing the characteristic biphasic pulsed-Doppler flow signals. CFR were determined as the ratio of hyperemic, 
induced by intravenous dypiridamole administration, to baseline diastolic coronary flow velocity. Patients were randomly assigned to bisoprolol and 
ivabradine for one month (after up-titration phase). CFR assessment was performed again at the end of treatment period.
results:  There were no significant differences in baseline characteristics between ivabradine and bisoprolol group. CFR was successfully performed 
in all patients. Baseline CFR was not significantly different in ivabradine and bisoprolol group (2.68 ± 0.56 vs. 2.74 ± 0.58 - p = ns). After 1 month 
CFR significantly increased in both groups (ivabradine: 3.52 ± 0.64 vs. 2.68 ± 0.56 - p < 0.01 - bisoprolol: 3.36 ± 0.70 vs. 2.74 ± 0.86 - p < 
0.01) but it was significantly better in ivabradine group compared with bisoprolol group (3.52 ± 0.64 vs. 3.36 ± 0.70 - p < 0.01), despite a similar 
lowering of heart rate (62 ± 7 vs. 60 ± 6 - p = ns). No patient dropped out during therapy.
conclusions:  In patients with stable CAD ivabradine has a better effect on improving CFR, compared with bisoprolol, despite similar lowering of 
heart rate. These is probably due to a better effect of ivabradine on diastolic phase of cardiac cycle.
